Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

GlaxoSmithKline1 enrolled

Overview

This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and the quadrivalent HPV vaccine (HPV-2).

This study uses a prevalence-based model (by using efficacy data from each vaccine's respective trials and published cost data for Taiwan) which estimates the differences in lesions, genital warts, cervical cancer and costs from a healthcare payer's perspective prevented between HPV-1 and HPV-2 vaccines during one year (when all women are vaccinated). It also analyses costs from a societal perspective.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Human Papillomavirus Infection

Interventions

Prevalence-based modelOTHER

Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).

Eligibility

Sex: FEMALEHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan (hypothetical group). Exclusion Criteria: * Not applicable.

Outcomes

Primary Outcomes

Annual number of lesions prevented by each vaccine

Time frame: Over a one-year period

Lesion related total cost averted by each vaccine

Time frame: Over a one-year period

Additional costs averted by HPV-1 vaccine compared to HPV-2 vaccine

Time frame: Over a one-year period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.